EGFR and non-small cell lung carcinoma: As EGFR‐TKIs are ineffective to treat EGFR wild‐type NSCLC cells, we hypothesized that DYRK1A repression might be an effective strategy for AZD9291 sensitization by suppressing EGFR/Met in EGFR wild‐type NSCLC cells.